Ichnos Sciences Inc

MindMed is a New York-based company that focuses on improving patient outcomes through the development of novel drug candidates and digital therapeutics. With a mission to unlock the therapeutic potential of psychedelics and other innovative compounds, MindMed aims to address unmet patient needs in the fields of psychiatry, addiction, pain, and neurology. As a global leader in brain health, MindMed utilizes industry-leading drug development expertise to advance its pipeline of diverse therapeutic programs. With a world-class team of drug developers and digital medicine experts, the company is dedicated to providing innovative solutions for the major unmet medical needs in brain health disorders.Generated from the website

Celmatix Inc., based in New York City and Cambridge, MA, is a preclinical-stage biotechnology company focused on pioneering innovative therapies specifically for women's health, particularly in the realm of ovarian health. With a growing pipeline that includes programs targeting ovarian aging, infertility, and endometriosis, Celmatix aims to address significant unmet medical needs and advance the understanding of female biology. Recognized for its groundbreaking research, Celmatix has received substantial funding from the Advanced Research Projects Agency for Health (ARPAH) to accelerate its drug development initiatives. The company's commitment to creating tailored therapeutics reflects its belief that women deserve specialized treatments to enhance their health and longevity throughout their lives. Generated from the website

The Global Alliance for TB Drug Development Inc., based in New York, is a pioneering organization dedicated to the research and development of new and effective treatments for tuberculosis (TB). With a mission to transform TB therapy, the Alliance manages the largest pipeline of new TB drugs in history, aiming to make innovative treatments accessible to all who need them. Celebrating 25 years of commitment to eradicating TB, the organization focuses on developing faster, simpler, and more effective cures for the disease, particularly drug-resistant forms of TB. Through collaborations and initiatives like the multi-manufacturer strategy, the Alliance works tirelessly to ensure that advancements in TB treatment are available globally, reinforcing the idea that access to treatment is a fundamental human right. Generated from the website